Antihypertensive Drugs Market by Therapeutic Class (Diuretics, ACE Inhibitors, Calcium Channel Blockers, Vasodilators, Beta-adrenergic Blockers, and Others) and Distribution Channel (Retail Pharmacy, Hospital Pharmacy, E-commerce, and Others Distribution Channel): Global Opportunity Analysis and Industry Forecast, 2019–2026
- ALL3476387
- 222 Pages
- December 2019
- Healthcare
Antihypertensive drugs are employed for the treatment of patients suffering from hypertension. Hypertension is a medical condition, which involves rise in blood pressure in the arteries. Furthermore, the patient suffering from hypertension is highly susceptible to other complications, which include heart failure and aneurysm. Therefore, the treatment of this medical condition requires early diagnosis and management by the use of antihypertensive drugs. Some of the antihypertensive drugs available in the market include beta blockers, calcium channel blockers, and vasodilators. These drugs are prescribed by a physician, and are available in retail stores and hospital pharmacies.
The growth of the global antihypertensive market is driven by surge in incidence of hypertension across the globe. Furthermore, rise in awareness related to complications associated with hypertension is another major factor that fuels the growth of the market. Moreover, increase in geriatric population and sedentary lifestyle act as key drivers of the global market. However, recent patent expirations hinder the growth of the antihypertensive market. Conversely, surge in research related to antihypertensive drugs in emerging economies is expected to offer lucrative opportunities during the forecast period.
The global antihypertensive market size is segmented into therapeutic class, distribution channel, and region. On the basis of therapeutic class, the market is fragmented into diuretics, ACE inhibitors, calcium channel blockers, vasodilators, beta-adrenergic blockers, and others. Depending on distribution channel, it is segregated into retail pharmacy, hospital pharmacy, and e-commerce. Region wise, it is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• This report entails a detailed quantitative analysis along with the current global antihypertensive market trends from 2019 to 2026 to identify the prevailing opportunities along with the strategic assessment.
• The market size and estimations are based on a comprehensive analysis of key developments in the industry.
• A qualitative analysis based on innovative products facilitates strategic business planning.
• The development strategies adopted by the key market players are enlisted to understand the competitive scenario of the market
Key Market Segments
• By Therapeutic Class
o Diuretics
o ACE Inhibitors
o Calcium Channel Blockers
o Beta-adrenergic Blockers
o Vasodilators
o Others
• By Distribution Channel
o Retail Pharmacy
o Hospital Pharmacy
o E-commerce
• By Region
o North America
U.S.
Canada
Mexico
o Europe
Germany
France
UK
Italy
Spain
Rest of Europe
o Asia-Pacific
Japan
China
India
Australia
South Korea
Rest of Asia-Pacific
o LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
List of key players profiled in the report
• Boehringer Ingelheim GmbH
• Merck KGaA
• Johnson and Johnson
• Bayer AG
• Pfizer, Inc.
• Takeda Pharmaceutical Co., Ltd.
• AstraZeneca plc
• Daiichi Sankyo Company
• Sanofi S.A.
• Novartis International AG
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Merck
• United Therapeutics Corporation Safe In Breastfeeding
1.1. Report Description
1.2. Key Market Segments
1.2.1. List of Key Players Profiled In The Report
1.3. Research Methodology
1.3.1. Primary Research
1.3.2. Secondary Research
1.3.3. Analyst Tools And Models
Chapter 2: Executive Summary
2.1. Key Findings of The Study
2.2. Cxo Perspective
Chapter 3: Market Overview
3.1. Market Definition And Scope
3.2. Top Player Positioning
3.2.1. Top Investment Pockets
3.3. Key Forces Shaping Antihypertensive Industry/Market
3.4. Market Dynamics
3.4.1. Drivers
3.4.1.1. Surge In Geriatric Population Worldwide
3.4.1.2. Surge In Healthcare Expenditure Worldwide
3.4.1.3. Rise In Prevalence of Hypertension Across The Globe
3.4.2. Restraint
3.4.2.1. Patent Expirations of Blockbuster Drugs
3.4.3. Opportunity
3.4.3.1. High Growth Potential In Developing Economies
3.4.4. Impact Analyses
Chapter 4: Antihypertensive Drugs Market, By Drug Class
4.1. Overview
4.1.1. Market Size And Forecast
4.2. Diuretics
4.2.1. Key Market Trends, Growth Factors, And Opportunities
4.2.2. Market Size And Forecast, By Region
4.2.3. Market Analysis By Country
4.3. Ace Inhibitors
4.3.1. Key Market Trends, Growth Factors, And Opportunities
4.3.2. Market Size And Forecast, By Region
4.3.3. Market Analysis By Country
4.4. Calcium Channel Blockers
4.4.1. Key Market Trends, Growth Factors, And Opportunities
4.4.2. Market Size And Forecast, By Region
4.4.3. Market Analysis By Country
4.5. Beta-Adrenergic Blockers
4.5.1. Key Market Trends, Growth Factors, And Opportunities
4.5.2. Market Size And Forecast, By Region
4.5.3. Market Analysis By Country
4.6. Vasodilators
4.6.1. Key Market Trends, Growth Factors, And Opportunities
4.6.2. Market Size And Forecast, By Region
4.6.3. Market Analysis By Country
4.7. Others
4.7.1. Key Market Trends, Growth Factors, And Opportunities
4.7.2. Market Size And Forecast, By Region
4.7.3. Market Analysis By Country
Chapter 5: Antihypertensive Drugs Market, By End User
5.1. Overview
5.1.1. Market Size And Forecast
5.2. Retail Pharmacy
5.2.1. Market Size And Forecast, By Region
5.2.2. Market Analysis By Country
5.3. Hospital Pharmacy
5.3.1. Market Size And Forecast, By Region
5.3.2. Market Analysis By Country
5.4. E-Commerce Websites & Online Drug Stores
5.4.1. Market Size And Forecast, By Region
5.4.2. Market Analysis By Country
Chapter 6: Antihypertensive Drugs Market, By Region
6.1. Overview
6.1.1. Market Size And Forecast
6.2. North America
6.2.1. Key Market Trends And Opportunities
6.2.2. Market Analysis, By Country
6.2.2.1. U.S.
6.2.2.1.1. U.S. Market Size And Forecast, By Drug Class
6.2.2.1.2. U.S. Market Size And Forecast, By Distribution Channel
6.2.2.2. Canada
6.2.2.2.1. Canada Market Size And Forecast, By Drug Class
6.2.2.2.2. Canada Market Size And Forecast, By Distribution Channel
6.2.2.3. Mexico
6.2.2.3.1. Mexico Market Size And Forecast, By Drug Class
6.2.2.3.2. Mexico Market Size And Forecast, By Distribution Channel
6.2.3. North America Market Size And Forecast, By Drug Class
6.2.4. North America Market Size And Forecast, By Distribution Channel
6.3. Europe
6.3.1. Key Market Trends And Opportunities
6.3.2. Market Analysis, By Country
6.3.2.1. Germany
6.3.2.1.1. Germany Market Size And Forecast, By Drug Class
6.3.2.1.2. Germany Market Size And Forecast, By Distribution Channel
6.3.2.2. France
6.3.2.2.1. France Market Size And Forecast, By Drug Class
6.3.2.2.2. France Market Size And Forecast, By Distribution Channel
6.3.2.3. Uk
6.3.2.3.1. Uk Market Size And Forecast, By Drug Class
6.3.2.3.2. Uk Market Size And Forecast, By Distribution Channel
6.3.2.4. Italy
6.3.2.4.1. Italy Market Size And Forecast, By Drug Class
6.3.2.4.2. Italy Market Size And Forecast, By Distribution Channel
6.3.2.5. Rest of Europe
6.3.2.5.1. Rest of Europe Market Size And Forecast, By Drug Class
6.3.2.5.2. Rest of Europe Market Size And Forecast, By Distribution Channel
6.3.3. Europe Market Size And Forecast, By Drug Class
6.3.4. Europe Market Size And Forecast, By Distribution Channel
6.4. Asia-Pacific
6.4.1. Key Market Trends And Opportunities
6.4.2. Market Analysis, By Country
6.4.2.1. Japan
6.4.2.1.1. Japan Market Size And Forecast, By Drug Class
6.4.2.1.2. Japan Market Size And Forecast, By Distribution Channel
6.4.2.2. China
6.4.2.2.1. China Market Size And Forecast, By Drug Class
6.4.2.2.2. China Market Size And Forecast, By Distribution Channel
6.4.2.3. India
6.4.2.3.1. India Market Size And Forecast, By Drug Class
6.4.2.3.2. India Market Size And Forecast, By Distribution Channel
6.4.2.4. Rest of Asia-Pacific
6.4.2.4.1. Rest of Asia-Pacific Market Size And Forecast, By Drug Class
6.4.2.4.2. Rest of Asia-Pacific Market Size And Forecast, By Distribution Channel
6.4.3. Asia-Pacific Market Size And Forecast, By Drug Class
6.4.4. Asia-Pacific Market Size And Forecast, By Distribution Channel
6.5. Lamea
6.5.1. Key Market Trends And Opportunities
6.5.2. Market Analysis, By Country
6.5.2.1. Brazil
6.5.2.1.1. Brazil Market Size And Forecast, By Drug Class
6.5.2.1.2. Brazil Market Size And Forecast, By Distribution Channel
6.5.2.2. South Africa
6.5.2.2.1. South Africa Market Size And Forecast, By Drug Class
6.5.2.2.2. South Africa Market Size And Forecast, By Distribution Channel
6.5.2.3. Saudi Arabia
6.5.2.3.1. Saudi Arabia Market Size And Forecast, By Drug Class
6.5.2.3.2. Saudi Arabia Market Size And Forecast, By Distribution Channel
6.5.2.4. Rest of Lamea
6.5.2.4.1. Rest of Lamea Market Size And Forecast, By Drug Class
6.5.2.4.2. Rest of Lamea Market Size And Forecast, By Distribution Channel
6.5.3. Lamea Market Size And Forecast, By Drug Class
6.5.4. Lamea Market Size And Forecast, By Distribution Channel
Chapter 7: Company Profiles
7.1. Astrazeneca Plc
7.1.1. Company Overview
7.1.2. Company Snapshot
7.1.3. Operating Business Segments
7.1.4. Product Portfolio
7.1.5. Business Performance
7.2. Boehringer Ingelheim International Gmbh
7.2.1. Company Overview
7.2.2. Company Snapshot
7.2.3. Operating Business Segments
7.2.4. Product Portfolio
7.2.5. Business Performance
7.3. Daiichi Sankyo Company, Limited
7.3.1. Company Overview
7.3.2. Operating Business Segments
7.3.3. Product Portfolio
7.3.4. Business Performance
7.3.5. Key Strategic Moves And Developments
7.4. Johnson & Johnson
7.4.1. Company Overview
7.4.2. Company Snapshot
7.4.3. Operating Business Segments
7.4.4. Product Portfolio
7.4.5. Business Performance
7.5. Lupin
7.5.1. Company Overview
7.5.2. Company Snapshot
7.5.3. Operating Business Segments
7.5.4. Product Portfolio
7.5.5. Business Performance
7.6. Novartis Ag.
7.6.1. Company Overview
7.6.2. Company Snapshot
7.6.3. Operating Business Segments
7.6.4. Product Portfolio
7.6.5. Business Performance
7.7. Merck & Co., Inc
7.7.1. Company Overview
7.7.2. Company Snapshot
7.7.3. Operating Business Segments
7.7.4. Product Portfolio
7.7.5. Business Performance
7.8. Pfizer Inc.
7.8.1. Company Overview
7.8.2. Company Snapshot
7.8.3. Operating Business Segments
7.8.4. Product Portfolio
7.8.5. Business Performance
7.9. Sun Pharmaceutical Industries Ltd. (Ranbaxy Laboratories)
7.9.1. Company Overview
7.9.2. Company Snapshot
7.9.3. Operating Business Segments
7.9.4. Product Portfolio
7.9.5. Business Performance
7.9.6. Key Strategic Moves And Developments
7.10. Sanofi
7.10.1. Company Overview
7.10.2. Operating Business Segments
7.10.3. Product Portfolio
7.10.4. Business Performance
Table 01. Global Antihypertensive Drugs Market, By Drug Class, 2018-2026 ($Million)
Table 02. Diuretics Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 03. Ace Inhibitors Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 04. Calcium Channel Blockers Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 05. Beta-Adrenergic Blockers Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 06. Vasodilators Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 07. Others Antihypertensive Drugs Market, By Region, 2018–2026 ($Million)
Table 08. Global Antihypertensive Drugs Market, By Distribution Channel, 2018-2026 ($Million )
Table 09. Antihypertensive Drugs Market Revenue For Retail Pharmacy, By Region 2018–2026($Million)
Table 10. Antihypertensive Drugs Market Revenue For Hospital Pharmacy, By Region 2018–2026 ($Million)
Table 11. Antihypertensive Drugs Market Revenue For E-Commerce Websites & Online Drug Stores, By Region 2018–2026 ($Million)
Table 12. Antihypertensive Drugs Market, By Region, 2018-2026 ($Million)
Table 13. North America Antihypertensive Drugs Market Revenue, By Country, 2019–2026 ($Million)
Table 14. U.S. Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 15. U.S. Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 16. Canada Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 17. Canada Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 18. Mexico Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 19. Mexico Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 20. North America Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026($Million)
Table 21. North America Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026($Million)
Table 22. Europe Antihypertensive Drugs Market Revenue, By Country, 2019–2026 ($Million)
Table 23. Germany Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 24. Germany Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 25. France Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 26. France Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 27. Uk Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 28. Uk Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 29. Italy Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 30. Italy Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 31. Rest of Europe Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 32. Rest of Europe Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 33. Europe Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026($Million)
Table 34. Europe Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026($Million)
Table 35. Asia-Pacific Antihypertensive Drugs Market Revenue, By Country, 2019–2026 ($Million)
Table 36. Japan Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 37. Japan Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 38. China Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 39. China Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 40. India Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 41. India Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 42. Rest of Asia-Pacific Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 43. Rest of Asia-Pacific Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 44. Asia-Pacific Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026($Million)
Table 45. Asia-Pacific Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026($Million)
Table 46. Lamea Antihypertensive Drugs Market Revenue, By Country, 2019–2026 ($Million)
Table 47. Brazil Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 48. Brazil Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 49. South Africa Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 50. South Africa Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 51. Saudi Arabia Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 52. Saudi Arabia Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 53. Rest of Lamea Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026 ($Million)
Table 54. Rest of Lamea Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026 ($Million)
Table 55. Lamea Antihypertensive Drugs Market Revenue, By Drug Class, 2019–2026($Million)
Table 56. Lamea Antihypertensive Drugs Market Revenue, By Distribution Channel, 2019–2026($Million)
Table 57. Astrazeneca: Company Snapshot
Table 58. Astrazeneca: Operating Business Segments
Table 59. Astrazeneca: Product Portfolio
Table 60. Boehringer Ingelheim: Company Snapshot
Table 61. Boehringer Ingelheim: Product Business Segments
Table 62. Boehringer Ingelheim: Product Portfolio
Table 63. Daiichi-Sankyo.: Company Snapshot
Table 64. Daiichi-Sankyo.: Operating Business Segments
Table 65. Daiichi-Sankyo.: Product Portfolio
Table 66. J&J: Company Snapshot
Table 67. J&J: Operating Business Segments
Table 68. J&J: Product Portfolio
Table 69. Lupin: Company Snapshot
Table 70. Lupin: Operating Segments
Table 71. Lupin: Product Portfolio
Table 72. Novartis: Company Snapshot
Table 73. Novartis: Operating Business Segments
Table 74. Novartis: Product Portfolio
Table 75. Merck: Company Snapshot
Table 76. Merck: Operating Segments
Table 77. Merck: Product Portfolio
Table 78. Pfizer: Company Snapshot
Table 79. Pfizer: Operating Segments
Table 80. Pfizer: Product Portfolio
Table 81. Sun Pharma: Company Snapshot
Table 82. Sun Pharma: Product Portfolio
Table 83. Sanofi: Company Snapshot
Table 84. Sanofi: Product Portfolio
Similar Reports
The global digital pathology market was valued at $3,323 million in 2016, and is expected to reach $8,668 million by 2023, registering a CAGR of 14.8% during the forecast period. Digital pathology is defined as an image-based information setting enabled b...
- Publish Date: February 26, 2018
- $5370
The global regenerative medicine market was valued at $5,444 million in 2016, and is estimated to reach $39,325 million by 2023, registering a CAGR of 32.2% from 2017 to 2023. Regenerative medicines are used to repair, replace, and regenerate tissues & organs that are affected owin...
- Publish Date: May 29, 2018
- $5370
The medical robotics and computer-assisted surgery is a combination of equipment, accessories, software, and services that aid in performing different functions, such as robotic minimally invasive and non-invasive radiosurgeries, rehabilitation therapies, and hospital & pharmacy automation. Surgical robotics...
- Publish Date: May 1, 2016
- $5370
